A CASE OF SYNCHRONOUS BILATERAL BREAST CANCER WITH DISCORDANT ESTROGEN RECEPTOR STATUS

Synchronous bilateral breast cancer is dened as two tumours diagnosed within 6 month interval and those above 6 months termed as metachronous breast cancer though there is difference in time interval specied by various clinicians. SBBC is a rare entity with incidence of 0.3 – 1.2% though it is recently increasing due to improved life expectancy after treatment and routine use of contralateral mammography. It is considered that synchronous breast tumours are independent tumours than to be secondary to metastatic spread from primary. Presence of indraductal component, different histology and different degree of differentiation implies that 2 they are independent tumors. Mostly women with BSBC are treated with aggressive measures as they are thought to be aggressive. Recently overall consensus is that bilateral breast cancer is amenable to breast conservation surgeries 1 without compromising surviva

Download Full-text

Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status

International Journal of Surgery Case Reports ◽

10.1016/j.ijscr.2018.10.016 ◽

2018 ◽

Vol 53 ◽

pp. 102-106 ◽

Cited By ~ 1

Author(s):

Sunny Dhadlie ◽

Joseph Whitfield ◽

Rasika Hendahewa

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Case Report ◽

Estrogen Receptor Status ◽

Bilateral Breast Cancer ◽

Receptor Status ◽

Synchronous Bilateral Breast Cancer

Download Full-text

A Case-Match Study Comparing Unilateral With Synchronous Bilateral Breast Cancer Outcomes

Journal of Clinical Oncology ◽

10.1200/jco.2011.35.0165 ◽

2011 ◽

Vol 29 (36) ◽

pp. 4763-4768 ◽

Cited By ~ 20

Author(s):

Alan M. Nichol ◽

Rinat Yerushalmi ◽

Scott Tyldesley ◽

Mary Lesperance ◽

Chris D. Bajdik ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Estrogen Receptor Status ◽

Bilateral Breast Cancer ◽

Local Therapy ◽

Positive Lymph Node ◽

Unilateral Breast Cancer ◽

Cancer Specific Survival ◽

Node Number ◽

Synchronous Bilateral Breast Cancer

Purpose There is controversy about whether patients with synchronous bilateral breast cancer (SBBC) have similar or worse outcomes compared with patients with unilateral breast cancer. The purpose of this study was to determine whether survival outcomes for patients with SBBC can be estimated from the characteristics of their individual cancers. Patients and Methods Patients had invasive breast cancer, without metastases or inflammatory disease, diagnosed in British Columbia between 1989 and 2000. There were 207 cases with SBBC (diagnosed ≤ 2 months apart) and 15,497 with unilateral breast cancer. By using 10-year breast cancer–specific survival (BCSS) estimates, the higher-risk cancer of each SBBC case was determined and matched with three breast cancers from the unilateral cohort to select 621 high-risk matches. The priority sequence of matching the prognostic and predictive variables was positive lymph node number, primary tumor size, age, grade, lymphovascular invasion, estrogen receptor status, local therapy used, margin status, treating clinic, diagnosis year, and type of systemic therapy used. Results With a median follow-up of 10.2 years, the overall 10-year BCSS was significantly higher for the unilateral cohort (81%; 95% CI, 81% to 82%) than for the SBBC cases (71%; 95% CI, 63% to 77%). The SBBC cases had significantly higher mean age and stage at presentation. The 10-year BCSS was 74% (95% CI, 69% to 77%) for the high-risk matches. Conclusion BCSS was not significantly different between the SBBC cases and their high-risk matches.

Download Full-text